Gilead Sciences (NASDAQ:GILD) Given a $88.00 Price Target at Mizuho

Mizuho set a $88.00 price target on Gilead Sciences (NASDAQ:GILD) in a research report report published on Monday, TipRanks reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

GILD has been the subject of a number of other research reports. BMO Capital Markets set a $76.00 price objective on shares of Gilead Sciences and gave the stock a buy rating in a research report on Monday. UBS Group upped their price objective on shares of L Brands from $26.00 to $28.00 and gave the stock a neutral rating in a research report on Wednesday, April 10th. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research note on Friday, April 26th. They set an outperform rating and a $82.00 target price for the company. ValuEngine cut shares of Intersect ENT from a buy rating to a hold rating in a research note on Monday, July 8th. Finally, Cantor Fitzgerald set a $88.00 target price on shares of Gilead Sciences and gave the stock a buy rating in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seventeen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $80.99.

NASDAQ GILD traded down $0.02 on Monday, reaching $66.92. 4,179,362 shares of the company’s stock traded hands, compared to its average volume of 6,241,528. The business has a 50 day moving average of $66.65. The stock has a market cap of $85.45 billion, a price-to-earnings ratio of 10.88, a price-to-earnings-growth ratio of 3.18 and a beta of 1.12. Gilead Sciences has a fifty-two week low of $60.32 and a fifty-two week high of $79.61. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.53 and a current ratio of 3.62.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.53 by $0.23. The business had revenue of $5.28 billion during the quarter, compared to the consensus estimate of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The company’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.48 earnings per share. On average, analysts expect that Gilead Sciences will post 6.6 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, June 13th. This represents a $2.52 annualized dividend and a yield of 3.77%. Gilead Sciences’s dividend payout ratio is presently 40.98%.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total value of $399,850.00. Following the transaction, the executive vice president now directly owns 27,198 shares in the company, valued at approximately $1,869,862.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Francis Cogan sold 2,700 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $62.61, for a total transaction of $169,047.00. Following the completion of the transaction, the director now owns 57,560 shares in the company, valued at $3,603,831.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,384 shares of company stock valued at $755,002. 0.20% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the business. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp lifted its holdings in shares of Gilead Sciences by 95.7% in the 4th quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 554,083 shares of the biopharmaceutical company’s stock worth $34,658,000 after acquiring an additional 271,000 shares during the last quarter. Nicholas Company Inc. lifted its holdings in shares of Gilead Sciences by 2.7% in the 4th quarter. Nicholas Company Inc. now owns 506,760 shares of the biopharmaceutical company’s stock worth $31,697,000 after acquiring an additional 13,500 shares during the last quarter. AIMZ Investment Advisors LLC lifted its holdings in shares of Gilead Sciences by 39.9% in the 4th quarter. AIMZ Investment Advisors LLC now owns 53,738 shares of the biopharmaceutical company’s stock worth $3,361,000 after acquiring an additional 15,333 shares during the last quarter. Western Wealth Management LLC acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $267,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of Gilead Sciences in the 1st quarter worth approximately $2,305,000. Institutional investors own 78.69% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: How to find the components of the quick ratio

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.